Zhangjiang Life Health Industry Annual Rising Stars 2024 Announced: Showcasing Innovation in AI Pharma, Synthetic Biology, and Medical Devices
MindRank
AI Drug Developer
Ailomics
Innovative Drug Developer
On November 17, the "Zhangjiang Life Science and Health Industry Annual Rising Stars/Companies · 2024" list was officially announced, with 10 rising companies and 8 rising individuals receiving this honor.
This is the third "Zhangjiang Life Health Industry Annual Rising Star" list. The selection of rising stars and companies aims to promote the spirit of innovation, highlight innovative practices and achievements, set benchmarks for the industry, and lead the future.
The Emerging Figures and Enterprises RatedInnovative Technology, Product Launch, Clinical Breakthroughs, Capital MarketsAll aspects have shown quite impressive performance.
● MindRank (Shanghai) Science and Technology Co., Ltd.
In September this year, MindRank released the world's largest single-property ADMET open-source dataset, PharmaBench. The Phase IIb clinical trial of MDR-001, a novel small-molecule oral GLP-1RA drug designed with their self-developed AI-assisted technology, has completed the first dosing group.
MindRank has gained widespread recognition both in China and internationally. To date this year, MindRank has successively received several honors, including being named among the "Top 200 Most Promising Health Tech Companies in East Asia" by HolonIQ, "China's Most Promising Biotech Startup 2024" by Global Health & Pharma, and "China's Most Socially Impactful Startup Companies 2024" by Fortune.
● CrystalMind Therapeutics (Shanghai) Co., Ltd.
MindRank has built an AI robot innovation R&D platform that integrates common technologies such as artificial intelligence and robotic experiments, oriented towards future industries, and has scaled up the deployment of AI robot laboratories.
In response to the challenges of GPCR antigen preparation and the time-consuming nature of manually drawing chemical structures, MindRank has launched the XrossXeven™, a one-stop platform for GPCR antibody discovery, and PatSight, a patent data mining platform, both empowered by AI, to enhance the efficiency of compound discovery and analysis.
● Ailomics Therapeutics Co., Ltd.
Ailomics Chooses a Unique Path for New Drug Development: "From Clinic to Research and Back to Clinic." This approach starts with patient samples and clinical data, using AI-enhanced bioinformatics analysis to identify key signaling pathways responsible for disease progression and potential innovative drug targets.
Ailomics has built five technology platforms — computational, organ-on-a-chip, in vivo pharmacology, in vitro pharmacology, and biologics — and has currently discovered multiple new targets for immune diseases, which have been preliminarily validated in animal models.
● Insilico Medicine (Shanghai) Co., Ltd.
Insilico Medicine, which introduced the world’s first generative AI platform to fully assist in drug discovery and design, released several AI-powered software and hardware tools this year, including the innovative algorithm "Quantum Computing-Assisted Fragment Automatic Structure Generator" (QFASG), the large language model nach0 developed in collaboration with NVIDIA, and the AI hardware PandaOmics Box.
In September this year, Insilico Medicine announced positive results from the Phase IIa clinical trial of the world’s first “AI drug” ISM001-055, which was discovered by AI identifying a novel target and designed by AI creating an innovative molecular structure. This marks the first patient population validation for a truly AI-driven drug.
● Shanghai Changjin Biotechnology Co., Ltd.
Changjin Bio has more than 10 patents in the fields of food synthetic biology and microbial protein. Its first production line has obtained food production permission and has been put into operation, making it one of the leading companies in the global edible microbial protein field to reach the industrialization threshold.
Changjin Bio's main products include milk proteins secreted by "cell factories" and microbial cell proteins. The second-generation products have efficiently completed the biosynthesis and expression of milk proteins from more than ten mammalian species, including cows, sheep, and cats.
● BrainLink Medical Technology (Shanghai) Co., Ltd.
Recently, the brain-computer interface product NEO from Boyicro Medical successfully completed the third clinical trial implantation surgery in China and the first in Shanghai, utilizing innovative technologies such as the self-developed "Online Time-Domain and Spatial-Domain Brain Function Localization System" for the first time.
NEO uses a semi-invasive technology that is less likely to fall off and does not need to directly contact brain cells. It has a smaller size compared to similar products and does not require battery replacement. Currently, patients who have undergone clinical trial surgeries have shown good recovery, with some even regaining partial hand movement function.
● Shanghai Aoyi Information Technology Co., Ltd.
AuoicTechnologies focusing on human bioelectric sensing, AI-based pattern recognition for electromyography and electroencephalography, and intelligent bionic prosthetics.And Intelligent Stroke Rehabilitation System.
AOi Technology this year unveiled its latest achievements in intelligent robot technology and brain-computer interfaces, and for the first time applied EEG signal control technology to its self-developed ROHand dexterous hand, realizing direct interaction between the human brain and robotic devices.
● Shanghai Stepped Medical Technology Co., Ltd.
Ladder Medical has developed a full-stack neuro-electrophysiological solution, including HNE ultra-flexible micro-nano electrodes, StairPlex high-throughput neural signal acquisition system, and AUFEIS portable implantation system.
The hardware of this system features ultra-flexibility, ultra-miniaturization, high throughput, high density, high biocompatibility, and low invasiveness, while the software is capable of handling data acquisition, processing, and analysis. The implant system provides a one-stop solution for electrode implantation.
● KaiXing Life Technologies (Shanghai) Co., Ltd.
In February this year, KarryCell's autologous BCMA-targeted CAR-T cell product, Saikaze® (Zevor-cel Injection), was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory multiple myeloma.
SaiKaiZe® Becomes the First CAR-T Product Fully Independently Developed in Shanghai and the Fifth CAR-T Product Approved for Marketing in China.
● Shanghai Antech Medical Technology Co., Ltd.
Antic Medical Receives Approval for Two Class III Medical Device Registrations This Year, Demonstrating Innovation Strength: "Cryotherapy Ablation System" Approved for Marketing on July 5; "Balloon Cryoablation Catheter" Approved for Marketing on August 6.
The combination of the two is used for the treatment of drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation in adult patients. It can ensure the efficacy of cryoablation while reducing damage to adjacent tissues and lowering clinical and procedural risks such as myocardial injury caused by early balloon retraction and difficulty in balloon sheathing.
● Shanghai Lanmai Medical Technology Co., Ltd.
In August this year, Lanmai Medical's "Venous Stent System" obtained the Class III medical device registration certificate issued by the National Medical Products Administration for the treatment of non-thrombotic iliac vein compression syndrome, deep vein thrombosis, and post-thrombotic syndrome.
Among them, the stent adopts an integrated weaving method, featuring different mesh densities. The design that combines dense and sparse meshes can effectively meet the clinical requirements for stent support and flexibility.
● Shanghai Taoying Medical Technology Co., Ltd.
Taoying Medical is committed to using digital medical methods to provide orthopedic doctors with better diagnostic tools and medical solutions.
This year, the spinal surgery AI medical image processing software independently developed by SiPuNai Medical, under TaoYing Medical, has been officially approved for registration. The software is mainly used to assist spinal screening workers and clinical doctors in automatically, comprehensively, and fully evaluating patients' spinal conditions.
● Xin Kai Luo Medical Technology (Shanghai) Co., Ltd.
Xin Kai Luo Medical had multiple specifications and products approved for marketing both domestically and internationally this year, including:
✎SkyFlow® Intracranial Thrombectomy Stent Approved for Registration in Vietnam;
✎SkyFlow® Intracranial Thrombectomy Stent Approved for Registration in Morocco;
✎SkyLoach® Intracranial Balloon Dilation Catheter Receives Approval for New Specifications;
✎Hydrus® RX Carotid Balloon Dilation Catheter Approved for Marketing.
● Fukang (Shanghai) Health Technology Co., Ltd.
PharmaFocus has made several breakthroughs and advancements in clinical aspects this year, including:
✎CVL009 (Neratinib Maleate Tablets) Phase II clinical trial for the first indication proceeds smoothly; Phase II clinical trial for the second indication approved; Granted Orphan Drug Designation by the FDA.
✎CVL237 has been approved to initiate a Phase II clinical trial for a second indication, and a third new indication clinical trial has also been approved, making it the first PI3K inhibitor in China approved for clinical trials to treat APDS.
✎Phase II Clinical Trial of SHEN211, a Novel Class 1 Drug Developed in Collaboration, is Proceeding Smoothly.
● Shanghai Chengyi Biotechnology Co., Ltd.
Recently, the film-coated tablets of AZD5004, a Class 1 new drug developed by EternityBio, have been approved in China for clinical trials on two indications. The drug is intended for long-term weight management in overweight or obese adults with at least one obesity-related comorbidity, as well as for the treatment of patients with type 2 diabetes.
Previously, Ecentria Biosciences reached an exclusive licensing agreement with AstraZeneca for up to over $2 billion in China regarding the film-coated tablet AZD5004, which is considered a potential blockbuster next-generation GLP-1 therapy.
● Crystal Core Biopharmaceutical Technology (Shanghai) Co., Ltd.
In July this year, Crystal nucleus Biotechnology announced that it has completed nearly 100 million yuan in A round financing, led by Huajin Investment and Huajin Avenue, followed by Tigermed, and continued investment from existing shareholders Gaorong Venture Capital and Licheng Capital. The financing funds will be mainly used for the global Phase I/II clinical trials of JH02.68Ga-JH03/177Lu-JH04The IND application and clinical development in China and the US.
Crystal Core Biotech focuses on visualized diagnosis-treatment integrated targeted radionuclide therapy (TRT). It has successfully built a proprietary technology platform for targeted radiopharmaceutical development and has become the first company in China to gain dual IND approvals in the TRT field in both China and the U.S.
● Shanghai Innostar Biotechnology Co., Ltd.
In September this year, Innostar successfully listed on the STAR Market of the Shanghai Stock Exchange, achieving the first pharmaceutical STAR Market IPO in China this year.
As one of the earliest companies in China to simultaneously obtain GLP certification from NMPA and OECD, as well as pass the GLP inspection by the U.S. FDA, Innostar aligns with international standards and possesses competitive international service capabilities within the industry, providing comprehensive new drug research services that meet both domestic and international submission standards for pharmaceutical enterprises and research institutions worldwide.
Zhangming Niu
Founder and CEO of MindRank (Shanghai) Science and Technology Co., Ltd.
Feng Ren
Insilico Medicine (Shanghai) Co., Ltd. Co-Chief Executive Officer,Chief Scientific Officer
Yu Haihua
Crystal Core Biopharmaceuticals (Shanghai) Co., Ltd. Co-Founder, CEO
Shen Xiaokun
Chairman of Focusen (Shanghai) Health Technology Co., Ltd.
Zhang Qing
Founder and Chief Executive Officer of Ailomics Therapeutics Co., Ltd.
Zhenxin Zhao
Founder, General Manager, and Chief Technology Officer (CTO) of Shanghai Sinocare Medical Technology Co., Ltd.
Ni Hualiang
Founder and General Manager of Shanghai Aoyi Information Technology Co., Ltd.
Cai Zongyuan
General Manager of Shanghai Taoying Medical Technology Co., Ltd.
Shanghai Antech Medical Technology Co., Ltd.
Shanghai Stepped Medical Technology Co., Ltd.
Shanghai Changjin Biotechnology Co., Ltd.
Shanghai Honest Pharm Co., Ltd.
Shanghai Innostar Biotechnology Co., Ltd.
Shanghai Fourier Intelligence Technology Co., Ltd.
Shanghai Lanmai Medical Technology Co., Ltd.
KaiXing Life Technologies (Shanghai) Co., Ltd.
BrainLink Medical Technology (Shanghai) Co., Ltd.
XtalPi Therapeutics (Shanghai) Co., Ltd.
Zhangjiang Medipost, as the most innovative and dynamic biopharmaceutical industry hub in China, continues to attract waves of research elites and innovative companies to establish roots and contribute to the development of Zhangjiang, injecting a constant flow of vitality into the biopharmaceutical industry in Zhangjiang and even Pudong.
2024-09-09
